Amplia Therapeutics Advances Narmafotinib Trial with New Daily Dosing Regimen
Event summary
- Amplia Therapeutics initiates Phase 2b study of narmafotinib with daily dosing in pancreatic cancer patients.
- Study designed in alignment with FDA feedback, aiming for registrational study submission.
- Patient enrollment planned to begin by Q4 2026, with safety and tolerability data expected by Q2 2027.
- Narmafotinib has received orphan drug and fast track designations from the U.S. FDA.
- Study will enroll patients across 3-4 sites in Australia.
The big picture
Amplia Therapeutics is advancing its narmafotinib program with a new Phase 2b study, exploring daily dosing in combination with standard chemotherapy for advanced pancreatic cancer. This move aligns with FDA feedback and leverages resources from the AMPLICITY study, highlighting the company's strategic focus on addressing high unmet needs in fibrotic cancers. The study's success could position narmafotinib as a best-in-class FAK inhibitor, potentially strengthening Amplia's pipeline and regulatory standing.
What we're watching
- Regulatory Alignment
- How FDA feedback will shape the registrational study submission and approval pathway.
- Execution Risk
- The pace at which patient enrollment and data collection will proceed, given the accelerated initiation.
- Therapeutic Potential
- Whether daily dosing of narmafotinib will enhance its therapeutic potential in pancreatic cancer.
Related topics